Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Return on Capital Employed (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Return on Capital Employed readings, the most recent being 243.94% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed fell 20840.0% to 243.94% in Q1 2026 year-over-year; TTM through Mar 2026 was 243.94%, a 20840.0% decrease, with the full-year FY2025 number at 13.81%, up 307351.0% from a year prior.
  • Return on Capital Employed hit 243.94% in Q1 2026 for Atara Biotherapeutics, down from 66.85% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 2561.91% in Q2 2024 to a low of 790.4% in Q4 2023.
  • Median Return on Capital Employed over the past 5 years was 6.25% (2025), compared with a mean of 298.43%.
  • Biggest five-year swings in Return on Capital Employed: skyrocketed 271543bps in 2024 and later plummeted -253888bps in 2025.
  • Atara Biotherapeutics' Return on Capital Employed stood at 95.59% in 2022, then plummeted by -727bps to 790.4% in 2023, then skyrocketed by 222bps to 962.15% in 2024, then tumbled by -93bps to 66.85% in 2025, then tumbled by -465bps to 243.94% in 2026.
  • The last three reported values for Return on Capital Employed were 243.94% (Q1 2026), 66.85% (Q4 2025), and 169.42% (Q3 2025) per Business Quant data.